PPLPHARMA

Piramal Pharma Share Price

₹255.00 -0.4 (-0.16%)

25 Dec, 2024 19:14

SIP TrendupStart SIP in PPLPHARMA

Start SIP

Performance

  • Low
  • ₹251
  • High
  • ₹257
  • 52 Week Low
  • ₹114
  • 52 Week High
  • ₹308
  • Open Price₹256
  • Previous Close₹255
  • Volume1,997,936

Investment Returns

  • Over 1 Month + 1.94%
  • Over 3 Month + 17.15%
  • Over 6 Month + 62.43%
  • Over 1 Year + 81.49%
SIP Lightning

Smart Investing Starts Here Start SIP with Piramal Pharma for Steady Growth!

Invest Now

Piramal Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 745.8
  • PEG Ratio
  • 5.6
  • Market Cap Cr
  • 33,807
  • P/B Ratio
  • 4.3
  • Average True Range
  • 11.77
  • EPS
  • 0.44
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.18
  • RSI
  • 48.69
  • MFI
  • 62.17

Piramal Pharma Financials

Piramal Pharma Technicals

EMA & SMA

Current Price
₹255.00
-0.4 (-0.16%)
pointer
  • stock-down_img
  • Bullish Moving Average 7
  • stock-up_img
  • Bearish Moving Average 9
  • 20 Day
  • ₹257.53
  • 50 Day
  • ₹250.46
  • 100 Day
  • ₹231.12
  • 200 Day
  • ₹200.99

Resistance and Support

254.35 Pivot Speed
  • R3 264.80
  • R2 261.10
  • R1 258.05
  • S1 251.30
  • S2 247.60
  • S3 244.55

What's your outlook on Piramal Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Piramal Pharma Ltd. provides pharmaceutical solutions, including contract manufacturing, active pharmaceutical ingredients (APIs), and consumer healthcare products. It serves global markets, offering high-quality healthcare products to pharmaceutical companies and end consumers.

Piramal Pharma has an operating revenue of Rs. 8,703.82 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 1% needs improvement, ROE of 0% is poor and needs improvement. The company has a reasonable debt to equity of 31%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 36% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 17% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 55 which is a POOR score indicating inconsistency in earnings, a RS Rating of 85 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 53 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Piramal Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-23 Quarterly Results
2024-07-26 Quarterly Results
2024-05-10 Audited Results & Final Dividend
2024-01-30 Quarterly Results
2023-10-27 Quarterly Results
Date Purpose Remarks
2024-07-12 FINAL Rs.0.11 per share(1.1%)Final Dividend

Piramal Pharma F&O

Piramal Pharma Shareholding Pattern

34.95%
11.21%
2.22%
13.73%
0%
13.29%
24.6%

About Piramal Pharma

  • NSE Symbol
  • PPLPHARMA
  • BSE Symbol
  • 543635
  • ISIN
  • INE0DK501011

Similar Stocks to Piramal Pharma

Piramal Pharma FAQs

Piramal Pharma share price is ₹255 As on 25 December, 2024 | 19:00

The Market Cap of Piramal Pharma is ₹33806.6 Cr As on 25 December, 2024 | 19:00

The P/E ratio of Piramal Pharma is 745.8 As on 25 December, 2024 | 19:00

The PB ratio of Piramal Pharma is 4.3 As on 25 December, 2024 | 19:00

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23